Sunesis Pharmaceuticals (NASDAQ: SNSS) is one of 189 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Sunesis Pharmaceuticals to similar companies based on the strength of its valuation, dividends, profitability, analyst recommendations, institutional ownership, risk and earnings.

Profitability

This table compares Sunesis Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sunesis Pharmaceuticals -1,472.94% N/A -125.56%
Sunesis Pharmaceuticals Competitors -3,262.61% -524.52% -39.32%

Earnings and Valuation

This table compares Sunesis Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Sunesis Pharmaceuticals $2.54 million -$38.02 million -1.62
Sunesis Pharmaceuticals Competitors $217.29 million -$39.39 million -74.35

Sunesis Pharmaceuticals’ competitors have higher revenue, but lower earnings than Sunesis Pharmaceuticals. Sunesis Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Sunesis Pharmaceuticals has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Sunesis Pharmaceuticals’ competitors have a beta of 1.56, suggesting that their average stock price is 56% more volatile than the S&P 500.

Institutional and Insider Ownership

38.4% of Sunesis Pharmaceuticals shares are held by institutional investors. Comparatively, 49.8% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 10.2% of Sunesis Pharmaceuticals shares are held by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Sunesis Pharmaceuticals and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sunesis Pharmaceuticals 0 2 1 0 2.33
Sunesis Pharmaceuticals Competitors 530 2442 6641 124 2.65

Sunesis Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 76.06%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.96%. Given Sunesis Pharmaceuticals’ higher probable upside, analysts plainly believe Sunesis Pharmaceuticals is more favorable than its competitors.

Summary

Sunesis Pharmaceuticals competitors beat Sunesis Pharmaceuticals on 8 of the 12 factors compared.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.